Viromed Medical AG initiates approval process for PulmoPlas(R) with the Federal Institute for Drugs and Medical Devices (BfArM)
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
RBI Data Reveals Divergence in Credit Card Spending and Debit Card Cash Withdrawals
-
First-time boat buyers advised to assess full ownership costs
-
Panthers expected to begin 2027 NRL season away from new stadium
-
Planning and preparation can reduce stress of interstate relocation
-
Sweet As app launches restaurant discovery platform
-
Two more arrested in Carrie Mullane suspected murder investigation
-
Phoenix Restaurants Offer Thanksgiving Dinner to Go for Pickup
-
MLA seeks inquiry into reported sectarian gestures on Ormeau Road
-
Mayo school appeals for information after convent and chapel vandalism
-
Louise O’Reilly attacks Simon Harris over unemployment remarks
-
Virginia overwhelms Arkansas 91-72 behind balanced scoring
-
Canadian soldier Aidan Goulding remembered at Vancouver funeral
-
Second major storm brings destructive winds and outages to British Columbia
-
Tayyab Arif hits 57 on Pakistan Test debut against Sri Lanka
-
Godzilla Minus Zero leads North American box office with $31.6m
-
Robert Trujillo discusses literacy and social justice children’s books
-
Advocate calls for coordinated support for children facing trafficking
-
Civil rights advocate William Bill Tucker dies aged 98
-
Medicare Open Enrollment Ends Dec. 7: Review Your Coverage Options
-
Pennsylvania Democrats secure state trifecta in midterm elections
-
US Treasury order targets bank transfers linked to crypto exchange MEXC
-
Godzilla Minus Zero sets foreign-language box-office opening record
-
Nvidia CEO Controversy Sparks Fears of Tighter U.S. AI Chip Curbs for Samsung and SK hynix
-
Eagles record six sacks as rushing attack struggles against Giants
-
Villeneuve teases James Bond casting at Los Angeles museum gala
-
Thames Water seeks to delay £12bn in debt repayments
-
Nottinghamshire launches specialist rural crime policing team
-
Newark boxing gym expands alternative education programme
-
China confirms talks over possible Xi-Putin-Trump summit
-
Democrats consider impeachment drive against Defence Secretary Hegseth
-
Rail journey offers a slower route to a Berlin city break
-
Energy bill plan could use HMRC income data to target support
-
Arsenal control title race as Manchester United fall into bottom three
-
Business owner earning £6,000 a month tackles £70,000 debt
-
Suspected Krakow gunman dies after attack that killed six
-
Nvidia chief faces inquiry after disclosing affair with suspected Chinese agent
-
Carrick backs Dalot after hostile reception from Manchester United fans
-
Comet returns as online electrical marketplace 14 years after collapse
-
Aston Villa Defy History With Rare Victory at Old Trafford
-
Brussels Education Unions Schedule Major November Protest Over Funding and Reforms
Viromed Medical AG initiates approval process for PulmoPlas(R) with the Federal Institute for Drugs and Medical Devices (BfArM)
RELLINGEN, DE / ACCESS Newswire / September 23, 2025 / Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has initiated the official approval process for its new product PulmoPlas® with the Federal Institute for Drugs and Medical Devices („Bundesinstitut für Arzneimittel und Medizinprodukte"; BfArM). With this step, the company is setting the course for the future widespread use of this novel therapy.
PulmoPlas® is an innovative medical device based on cold plasma technology for the treatment of severe respiratory diseases. It is designed to effectively combat ventilator-associated pneumonia (VAP) in particular, thus offering patients a much-needed new treatment option.
Uwe Perbandt, CEO of Viromed Medical AG, explains: "With PulmoPlas®, we have developed a product that has the potential to make a decisive impact on one of the greatest medical challenges of our time - the fight against antimicrobial resistance. The approval process that has now begun is therefore not only a milestone for Viromed, but also an important step in the fight against multi-resistant pathogens."
The BfArM approval process is a multi-stage procedure that Viromed is preparing in collaboration with renowned scientific partners. The Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI) are supporting Viromed with their scientific expertise.
In parallel with the regular approval process, Viromed will apply for special approval to ensure the availability of PulmoPlas® as early as possible.
The start of the approval process was preceded by a large study on the treatment of ventilator-associated pneumonia (VAP) with PulmoPlas® in intensive care patients; an ex vivo and in vivo study has already been initiated.
Further information on PulmoPlas® can be found at www.viromed.de/pulmoplas.
About Viromed Medical AG
Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.
Contact Viromed
E-Mail: [email protected]
Press contact
E-mail: [email protected]
SOURCE: Viromed Medical AG
View the original press release on ACCESS Newswire
L.Harper--AMWN
